1. Home
  2. EYE vs TSHA Comparison

EYE vs TSHA Comparison

Compare EYE & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo National Vision Holdings Inc.

EYE

National Vision Holdings Inc.

SELL

Current Price

$18.76

Market Cap

1.4B

Sector

Health Care

ML Signal

SELL

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

SELL

Current Price

$4.08

Market Cap

1.3B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
EYE
TSHA
Founded
1990
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Ophthalmic Goods
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.3B
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
EYE
TSHA
Price
$18.76
$4.08
Analyst Decision
Buy
Strong Buy
Analyst Count
11
13
Target Price
★ $27.00
$13.00
AVG Volume (30 Days)
2.1M
★ 3.1M
Earning Date
11-12-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 202.78
5.56
EPS
★ 0.78
N/A
Revenue
★ $1,987,488,000.00
$9,773,000.00
Revenue This Year
$2.20
N/A
Revenue Next Year
$4.73
$2,806.45
P/E Ratio
$23.32
★ N/A
Revenue Growth
9.00
★ 17.28
52 Week Low
$14.75
$3.46
52 Week High
$30.02
$7.30

Technical Indicators

Market Signals
Indicator
EYE
TSHA
Relative Strength Index (RSI) 58.15 43.65
Support Level $15.52 $3.92
Resistance Level $20.98 $4.57
Average True Range (ATR) 1.13 0.28
MACD 0.11 0.03
Stochastic Oscillator 84.35 23.77

Price Performance

Historical Comparison
EYE
TSHA

About EYE National Vision Holdings Inc.

National Vision Holdings Inc. is an optical retailer in the United States. Its product portfolio includes eyeglasses, sunglasses, contact lenses, accessories, and other related products. The company operates through a single operating segment. The Owned and Host segment includes the company-owned brands America's Best and Eyeglass World. In America's Best stores, vision care services are provided by optometrists or by independent professional corporations. The Host segment consists of Military and Fred Meyer locations, where eye exams are provided by independent optometrists.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

Share on Social Networks: